within Pharmacolibrary.Drugs.ATC.J;

model J06BD07
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.3333333333333336e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0081,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00317,
    k12             = 0.199,
    k21             = 0.199
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BD07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Casirivimab and imdevimab are recombinant human monoclonal antibodies that bind to non-overlapping epitopes of the spike protein of SARS-CoV-2, thereby blocking viral entry into human cells. They are used together as a combination therapy for the treatment and post-exposure prophylaxis of COVID-19. The combination received emergency use authorization during the COVID-19 pandemic.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults and COVID-19 patients; the following parameters are representative values from available regulatory and pharmacology reviews.</p><h4>References</h4><ol><li><p>Weinreich, DM, et al., &amp; Yancopoulos, GD (2021). REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. <i>The New England journal of medicine</i> 385(23) e81–None. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2108163&quot;>10.1056/NEJMoa2108163</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34587383/&quot;>https://pubmed.ncbi.nlm.nih.gov/34587383</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BD07;
